Case Report: Fournier Gangrene in a Diabetic Patient Using Dapagliflozin

Authors : Ceren Adali, Beyza Torun, Omer Zuhtu Yondem, Alper Bilal Özkardeş, Ayçe Çeliker

Pages : 48-52

Doi:10.33706/jemcr.1620485

View : 59 | Download : 39

Publication Date : 2025-06-29

Article Type : Other Papers

Abstract :Introduction: Fournier gangrene is a rare but severe necrotizing infection of the perineal region, requiring immediate medical attention. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, while effective in managing diabetes and providing cardiovascular benefits, have been linked to rare but serious adverse effects. In 2018, regulatory warnings highlighted a potential connection between these drugs and Fournier gangrene, though reported cases remain scarce. Case Report: This report details the case of a 59-year-old diabetic female who developed Fournier gangrene during dapagliflozin treatment. The patient presented with extensive perineal necrosis necessitating urgent surgical debridement and initiation of broad-spectrum antibiotics. Microbiological analysis identified Escherichia coli as causative pathogen. Intensive wound management and insulin adjustments led to significant clinical improvement, and the patient was discharged after 24 days. Conclusion: The possible link between SGLT-2 inhibitors and Fournier gangrene remains under investigation. While glucosuria induced by these medications may heighten the risk of infections, the presence of comorbidities such as diabetes and immunosuppression are likely contributing factors. This case emphasizes the complexity of determining causality. Clinicians prescribing SGLT-2 inhibitors should be vigilant for signs of rare infections like Fournier gangrene, especially in patients with multiple risk factors. Prompt diagnosis and aggressive treatment are critical for patient recovery.
Keywords : dapagliflozin, olgu sunumu, fournier gangreni, sodyum-glukoz kotransporter-2 inhibitörleri

ORIGINAL ARTICLE URL